Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Zimmer Holdings, Inc.    ZMH   US98956P1021

Delayed Quote. Delayed Nyse - 04/24 04:00:31 pm
101.97 USD   +11.50%
1h agoDJMARKET SNAPSHOT : U.S. Stocks End Choppy Session Higher
1h ago Apple buoys Nasdaq; Ukraine weighs on broader market
2h agoDJKKR Profit Edges Higher -- 2nd Update
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

Zimmer Holdings, Inc. : Zimmer Receives FDA Warning on Certain Hip Implants

10/01/2012 | 06:40pm US/Eastern

--Zimmer says FDA inspection of Puerto Rico plant turned up concerns about manufacturing of certain implants

--FDA in letter noted manufacturing, testing issues related to Trilogy Acetabuar System products, company says

--Zimmer says it is notifying customers of manufacturing issue, but hasn't withdrawn any products

(Adds context on metallic spikes in fourth paragraph and a no comment from Zimmer in seventh paragraph.)

   By Kristin Jones 

Zimmer Holdings Inc. (ZMH) said a U.S. Food and Drug Administration inspection of its plant in Puerto Rico turned up concerns about the manufacturing of certain hip implants.

The orthopedic maker's Zimmer Inc. subsidiary received a warning letter from the FDA dated Sept. 19, the company said in a regulatory filing Monday. In the letter, the FDA noted manufacturing and testing issues related to the company's Trilogy Acetabular System products, which are implanted in hip-replacement surgery.

Specifically, the U.S. drug regulator noted that Zimmer hadn't implemented a testing mechanism to show that its products met design specifications. The company also hadn't validated the effect of certain manufacturing operations on Trilogy products that incorporate metallic spikes.

Spikes are used to connect the hip replacement cup to a patient's bone when cement and screws are deemed insufficient.

The FDA requires that drug and medical-device makers undertake steps to ensure the quality of the design and manufacture of its products, known as process validation.

Zimmer said it is notifying customers of the manufacturing issue, but that it hasn't withdrawn any products. The company also said it previously suspended release of the spiked products, pending validation of the processes cited in the letter, and expects to complete validation in the next few weeks.

A Zimmer spokesman declined to comment further.

Shares gained 11 cents to $67.98 in after-hours trading. Through Monday's close, the stock was up 27% so far this year.

--Joseph Walker contributed to this article.

Write to Kristin Jones at

Subscribe to WSJ:

Recommend :
React to this article
Latest news on ZIMMER HOLDINGS, INC.
1h agoDJMARKET SNAPSHOT : U.S. Stocks End Choppy Session Higher
1h ago Apple buoys Nasdaq; Ukraine weighs on broader market
2h agoDJKKR Profit Edges Higher -- 2nd Update
2h agoDJU.S. Stocks Rise, Buoyed by Apple Results
3h agoDJZimmer to Buy Biomet for $13.35 Billion -- 5th Update
4h ago Zimmer to buy Biomet for $13.35 billion in latest consolidation
5h agoDJLONDON MARKETS : AstraZeneca, Smith & Nephew Push FTSE To 7-week High
5h agoDJMARKET SNAPSHOT : U.S. Stocks Rebound; Nasdaq Leads Gains
5h ago S&P 500 MOVERS : Xlnx, zmh
6h agoDJMARKET SNAPSHOT : U.S. Stocks Fluctuate On Russia Worries
Duration : Period :
Zimmer Holdings, Inc. Technical Analysis Chart | ZMH | US98956P1021 | 4-Traders
Income Statement Evolution
Zimmer Holdings, Inc. : Income Statement Evolution
More Financials
Dynamic quotes